BioSpace News Archive

MindMed, a leading clinical stage psychedelic medicine company, announced the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness.

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries

Cybin Files its 12 th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH™ 2.0" cannabidiol formulations in its second 2021 applied research and development study program, HYPER-A21-2.

RenBio , a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform, today announced that it has completed a $24 million Series A financing, led by Taiwan -based Ruentex Group.

At a crucial time when vaccination against potentially deadly diseases is top of mind, the National Meningitis Association is teaming up with award-winning actress, author and mother of three Molly Ringwald to encourage parents to talk to their teen’s doctor about the potentially life-saving second dose of the MenACWY vaccine for meningococcal disease.5

NeuPath Health Inc., owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and concussions, announced its financial and operating results for the three months ended March 31, 2021.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021.

ImmunoPrecise Moves SARS-CoV-2 PolyTope ™ Cocktail Program’s Path Toward IND Filing - Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment - Dr. Ilse Roodink and Dr. Debby Kruijsen to host live webinar “Function First: Using complementary antibody platforms to fight Covid-19” today at 11:00 am Eastern Daylight Time